1. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers
- Author
-
Ulf-Håkan Stenman, Francisco J. Esteva, Rafael Molina, Ie Ming Shih, Hans Jørgen Nielsen, Carsten Stephan, Michael J. Duffy, Lori J. Sokoll, Hans Lilja, Daniel W. Chan, Caj Haglund, Paul Sibley, Axel Semjonow, Nils Brünner, Nadia Harbeck, Daniel F. Hayes, Barry L. Dowell, George G. Klee, Harry G. Rittenhouse, Robert C. Bast, Leendert H. J. Looijenga, Rolf Lamerz, Barry Hoffman, Catharine M. Sturgeon, Mads Nikolaj Holten-Andersen, Eleftherios P. Diamandis, György Sölétormos, and Richard J. Babaian
- Subjects
Oncology ,Male ,medicine.medical_specialty ,Colorectal cancer ,medicine.medical_treatment ,Clinical Biochemistry ,Breast Neoplasms ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,Carcinoembryonic antigen ,Testicular Neoplasms ,Reference Values ,Internal medicine ,medicine ,Biomarkers, Tumor ,Humans ,Testicular cancer ,030304 developmental biology ,Gynecology ,Ovarian Neoplasms ,0303 health sciences ,biology ,business.industry ,Clinical Laboratory Techniques ,Biochemistry (medical) ,Cancer ,Prostatic Neoplasms ,medicine.disease ,3. Good health ,Prostate cancer screening ,030220 oncology & carcinogenesis ,biology.protein ,Female ,Hormone therapy ,business ,Ovarian cancer ,Colorectal Neoplasms - Abstract
Background: Updated National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been developed.Methods: Published reports relevant to use of tumor markers for 5 cancer sites—testicular, prostate, colorectal, breast, and ovarian—were critically reviewed.Results: For testicular cancer, α-fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase are recommended for diagnosis/case finding, staging, prognosis determination, recurrence detection, and therapy monitoring. α-Fetoprotein is also recommended for differential diagnosis of nonseminomatous and seminomatous germ cell tumors. Prostate-specific antigen (PSA) is not recommended for prostate cancer screening, but may be used for detecting disease recurrence and monitoring therapy. Free PSA measurement data are useful for distinguishing malignant from benign prostatic disease when total PSA is Conclusions: Implementation of these recommendations should encourage optimal use of tumor markers.
- Published
- 2016